This is an exploratory, single-center retrospective cohort real-world study comparing safety and efficacy of Fiasp® versus NovoRapid® when used in the Medtronic MiniMed 640G system in pediatric subjects with Type 1 Diabetes Mellitus
Inclusion Criteria: 1. Informed consent obtained by parents or legal caregivers before any trial-related activities. 2. Any age, age ≥ 2 years and age \<18 years at the time of signing informed consent 3. Documented diagnoses of T1DM ≥ 3 months prior to the beginning of the study 4. Using the Medtronic MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter for at least 30 days prior to beginning of the study and willing to continue using the system throughout the trial. 5. Ability and willingness to use the same insulin infusion sets throughout the trial 6. Using the same insulin for at least 30 days prior to screening 7. HbA1c \< 9.0% as assessed by local laboratory at screening 8. Ability and willingness to adhere to the protocol including performing SMBG (Self Monitoring Blood Glucose) profiles, attending visits, uploading pump and sensor data to the CareLink platform Exclusion Criteria: 1. Participation in another clinical trial within 28 days before the screening visit. Note: clinical trials do not include non-interventional studies 2. Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria within 30 days before screening 3. Anticipated significant change in lifestyle (e.g. eating, exercise or sleeping pattern) throughout the trial 4. Any diabetic complication including renal disease, retinopathy, etc 5. History of hospitalization for ketoacidosis ≤ 3 months prior to the day of screening 6. Any condition which, in the opinion of the Investigator, might influence patient's safety or compliance with the protocol